Terms: = Endocrine gland cancer AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Clinical Outcome
13 results:
1. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
2. Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian cancer.
Lee SW; Lee HY; Kang SW; Kim MJ; Lee YJ; Sung CO; Kim YM
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502561
[TBL] [Abstract] [Full Text] [Related]
3. A potential prognostic marker and therapeutic target: SPOCK1 promotes the proliferation, metastasis, and apoptosis of pancreatic ductal adenocarcinoma cells.
Li J; Ke J; Fang J; Chen JP
J Cell Biochem; 2020 Jan; 121(1):743-754. PubMed ID: 31478239
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Implications of Multiplex Detection of
Kim MK; Woo SM; Park B; Yoon KA; Kim YH; Joo J; Lee WJ; Han SS; Park SJ; Kong SY
Clin Chem; 2018 Apr; 64(4):726-734. PubMed ID: 29352043
[TBL] [Abstract] [Full Text] [Related]
5. A mathematical model of bimodal epigenetic control of miR-193a in ovarian cancer stem cells.
Cheng FH; Aguda BD; Tsai JC; Kochańczyk M; Lin JM; Chen GC; Lai HC; Nephew KP; Hwang TW; Chan MW
PLoS One; 2014; 9(12):e116050. PubMed ID: 25545504
[TBL] [Abstract] [Full Text] [Related]
6. cd117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients.
Huang R; Wu D; Yuan Y; Li X; Holm R; Trope CG; Nesland JM; Suo Z
PLoS One; 2014; 9(11):e112209. PubMed ID: 25380303
[TBL] [Abstract] [Full Text] [Related]
7. Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas.
Müssig K; Wehrmann T; Dittmann H; Wehrmann M; Ueberberg B; Schulz S; Bares R; Petersenn S
Clin Endocrinol (Oxf); 2012 Jul; 77(1):139-45. PubMed ID: 22248072
[TBL] [Abstract] [Full Text] [Related]
8. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma.
Chang DZ; Ma Y; Ji B; Wang H; Deng D; Liu Y; Abbruzzese JL; Liu YJ; Logsdon CD; Hwu P
Clin Cancer Res; 2011 Nov; 17(22):7015-23. PubMed ID: 21976550
[TBL] [Abstract] [Full Text] [Related]
9. Recurrent seminomas: clinical features and biologic implications.
Som A; Zhu R; Guo CC; Efstathiou E; Xiao L; Pisters LL; Matin A; Tu SM
Urol Oncol; 2012; 30(4):494-501. PubMed ID: 20822932
[TBL] [Abstract] [Full Text] [Related]
10. Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients.
Wimberger P; Roth C; Pantel K; Kasimir-Bauer S; Kimmig R; Schwarzenbach H
Int J Cancer; 2011 Jun; 128(11):2572-80. PubMed ID: 20715113
[TBL] [Abstract] [Full Text] [Related]
11. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract] [Full Text] [Related]
12. Motesanib diphosphate in progressive differentiated thyroid cancer.
Sherman SI; Wirth LJ; Droz JP; Hofmann M; Bastholt L; Martins RG; Licitra L; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Schlumberger MJ;
N Engl J Med; 2008 Jul; 359(1):31-42. PubMed ID: 18596272
[TBL] [Abstract] [Full Text] [Related]
13. Ceruminous adenomas: a clinicopathologic study of 41 cases with a review of the literature.
Thompson LD; Nelson BL; Barnes EL
Am J Surg Pathol; 2004 Mar; 28(3):308-18. PubMed ID: 15104293
[TBL] [Abstract] [Full Text] [Related]
